Pre-market hot trades in US stocks: Nvidia increases holdings and market expectations are raised, Coherent Corp. pre-market drops 3.20% attracting attention

Pre-market Hot Trades in US Stocks Coherent Corp. is down 3.20% in pre-market trading. Based on recent key news: On May 17, NVIDIA increased its stake in Coherent by acquiring 7.8 million shares. NVIDIA's proprietary investment portfolio holds stocks with a total market value of approximately $18.374 billion, up from $13 billion at the end of 2025, with holdings concentrated in AI ecosystem-related targets. NVIDIA's increased stake in Coherent Corp. (7.8 million shares) reflects its strategic initiative to support the artificial intelligence ecosystem, driving stock price fluctuations; On May 18, industry research firm LightCounting raised its growth forecast for the data communication market. JP Morgan analysts noted that this revision indicates stronger demand for optical communication devices such as optical modules, which is favorable for suppliers like Coherent, driving stock price fluctuations; On May 16, JP Morgan assigned an overweight rating to Coherent. Industry forecasts indicate that the non-CPO market will continue to maintain robust growth during this period, with a compound annual growth rate exceeding 20%. JP Morgan set a target price of $380 for Coherent, driving stock price fluctuations. The growth forecast for the data communication market has been raised, and demand for optical communication is strong. Top Gainers in Pre-market US Stocks Sunshine Biopharma is up 592.75% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. GeoVax Labs is up 164.23% in pre-market trading. Based on recent key news: On May 14, GeoVax Labs announced its strategic focus, emphasizing the prioritization of capital and operations on the GEO-MVA project while maintaining Gedeptin development as an important long-term option in combination immunotherapy. This strategic adjustment is considered the main reason for the significant increase in stock price. Source: SEC announcement On May 14, GeoVax Labs released original content through the EDGAR system, detailing its strategic adjustments and future development direction. The disclosure of this information has increased market confidence in the company's future growth potential, further driving the stock price up. Source: EDGAR system On May 14, the market reacted positively to GeoVax Labs' strategic adjustments, with investors expressing optimism about its long-term development potential in the field of combination immunotherapy, leading to a significant pre-market increase in stock price. Source: SEC announcement. The biotechnology industry has recently performed strongly, with evident capital inflow. Virax Biolabs is up 148.34% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation